Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US Hospitals [Yahoo! Finance]
Enlivex Therapeutics Ltd. - Ordinary Shares (ENLV)
Company Research
Source: Yahoo! Finance
Around the corner from the stadium where he once dazzled crowds as a receiver for the NFL team, Williams died in September 2023 at the age of 36. His cause of death was bacterial sepsis. A life-threatening emergency, sepsis occurs when the body's response to an infection damages vital organs. This overactive and toxic response can often lead to death, and sepsis is a threatening disease with a high unmet need for treatment. Each year, more than 1.7 million adults in the United States develop sepsis, with annual mortality of more than 270,000 due to the disease. Similar to a stroke or heart attack, this medical emergency requires swift action when it comes to diagnosis and treatment. Even if it's caught before becoming severe sepsis or septic shock, sepsis is the number one cost of hospitalization in the U.S., with acute sepsis hospitalization and skilled nursing reaching an estimated total of $62 billion annually. This is only a portion of all sepsis-related costs. Not only is t
Show less
Read more
Impact Snapshot
Event Time:
ENLV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ENLV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENLV alerts
High impacting Enlivex Therapeutics Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
ENLV
News
- Enlivex Therapeutics Ltd. (NASDAQ: ENLV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
- Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee OsteoarthritisGlobeNewswire
- Enlivex Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis [Yahoo! Finance]Yahoo! Finance
- Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee OsteoarthritisGlobeNewswire
- Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why [Yahoo! Finance]Yahoo! Finance
ENLV
Analyst Actions
- 4/23/24 - HC Wainwright
ENLV
Sec Filings
- 4/22/24 - Form 6-K
- 4/16/24 - Form 6-K
- 3/29/24 - Form 6-K
- ENLV's page on the SEC website